Parallax Volatility Advisers
KPTI icon

Parallax Volatility Advisers’s Karyopharm Therapeutics KPTI Stock Holding History

Parallax Volatility Advisers’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,200
Closed -$625K – 3098
2020
Q2 		$625K Buy
+2,200
New +$651K ﹤0.01% 1899
2016
Q4 		– Sell
-2,000
Closed -$292K – 3678
2016
Q3 		$292K Buy
+2,000
New +$240K ﹤0.01% 1698

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Parallax Volatility Advisers's KPTI Position: Q2 2019 in Review

Parallax Volatility Advisers sold out of Karyopharm Therapeutics (KPTI) in Q2 2019, closing a stake of 881 shares — an estimated $77K sold.

Parallax Volatility Advisers first reported a position in KPTI in Q4 2017 and held it in 2 quarters. The position peaked at $77K in Q1 2019. 103 funds tracked by Wall St. Rank hold KPTI as of Q2 2019.

  • Parallax Volatility Advisers reported no remaining Karyopharm Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 881 Karyopharm Therapeutics shares in Q2 2019, an estimated $77K.
  • Parallax Volatility Advisers first reported a position in Karyopharm Therapeutics in Q4 2017 and held it in 2 quarters.
  • Parallax Volatility Advisers's Karyopharm Therapeutics position peaked at $77K in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2019.

Based on Parallax Volatility Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.